Accordingly, we demonstrated in vivo that negatively modulating mGluR5 with a constitutive genetic ablation [30,50] or through a pharmacological blockade [51] significantly reduced glial activation and MN death, ameliorated the clinical progression and prolonged survival in SOD1G93A ALS mice. The gene discussed is GRM5; the disease is amyotrophic lateral sclerosis.